Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DUPI REDUCE Trial (DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema): a Multicenter, Low-intervention, Non-inferiority Randomized Controlled Trial, Embedded in the TREAT NL Registry

NCT06004986 is registered in ClinicalTrials.gov with Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) as lead sponsor.

NCT NCT06004986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06004986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DUPI REDUCE Trial (DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema): a Multicenter, Low-intervention, Non-inferiority Randomized Controlled Trial, Embedded in the TREAT NL Registry
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase
Phase 4
Overall status
Recruiting
Start date
August 14, 2023
Completion date
December 31, 2025
Enrollment
216 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis eczema